Aref Al-Kali, MD of Mayo Clinic discusses the important data presented on FLT3 mutant AML at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
Author: Editor
An educational overview of facts in Childhood Cancer | Pediatric Oncology (an educational tool designed to be shared by healthcare professionals with patients and caregivers)
Overview of facts in breast cancer (an educational tool designed to be shared by healthcare professionals with patients and caregivers)
H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy (vinorelbine+cisplatin) as adjuvant treatment for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8500: Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104)
H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced nonsquamous non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9094: First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.
H. Jack West, MD of Swedish Cancer Institute discusses an abstract that focused on the efficacy and safety of a third generation ALK inhibitor, lorlatinib, for ALK positive non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 9006: Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ARCHER 1050 trial for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take home of the POLLUX and CASTOR trials, which is the importance of early triplet therapy for relapsed patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology argues that the take-home message for the follow-up on the RESONATE trial is the role of ibrutinib for all types of CLL patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the take-home message of the LATITUDE study at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview of the POLLUX/CASTOR studies, which looked at daratumumab in combination with lenalidomide plus dexamethasone (DRd) and bortezomib plus dexamethasone in relapsed and refractory multiple myeloma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology discusses the LATITUDE trial, a phase III trial on androgen deprivation therapy (ADT) with abiraterone in newly diagnosed, high-risk, metastatic prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology gives an overview a four year follow-up study on the use of ibrutinib in previously treated patients with Chronic Lymphocytic Leukemia (CLL). This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology summarizes common questions that are asked regarding the updates study on the RESONATE trial, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 7510: Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains a common question that’s usually asked regarding the CASTOR/POLLUX study, which is whether or not you can split the dosing of daratumumab. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate cancer: androgen deprivation therapy plus abiraterone or androgen deprivation therapy plus docetaxel. He argues ADT plus abiraterone, but it ultimately depends on the physician and patient. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer
Katja Weisel, MD of Janssen Oncology gives an overview of her abstract, which focuses on two randomized phase III trials in relapsed or refractory multiple myeloma. DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8006: Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status
Katja Weisel, MD of Janssen Oncology explains further the next steps for the POLLUX and CASTOR trials which include extending the investigation of monoclonal antibodies in front line treatments. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Katja Weisel, MD of Janssen Oncology discusses the impact of the POLLUX and CASTOR trial on clinical practice, which are both already introduced in daily practice. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Katja Weisel, MD of Janssen Oncology summarizes a poster presentation that focused on the anti-CD38 antibody in refractory myeloma patients which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the next steps for the clinical trial at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy
Liza Villaruz, MD of University of Pittsburgh Medical Center discusses the impact of atezolizumab on clinical practice and future clinical research at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of the practice-changing data on lung cancer at the 2017 ASCO Annual Presentation in Chicago, IL.
Liza Villaruz, MD of University of Pittsburgh Medical Center gives an overview of her presentation, which focuses on the use of atezolizumab in advanced non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS9105: Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy
Jalaja Potluri, MD of AbbVie Inc. discusses what’s next for her study and her hopes for the drug to become FDA approved. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Jalaja Potluri, MD of AbbVie Inc. discusses common questions colleagues ask regarding her study at the 2017 ASCO Annual Meeting in Chicago, IL.
Jalaja Potluri, MD of AbbVie Inc. gives an overview of her abstract, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract TPS7069: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax Combined with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia
Jalaja Potluri, MD of AbbVie Inc. discusses the treatment trends for 2017 in acute myeloid leukemia at the 2017 ASCO Annual Meeting in Chicago, IL.
Nathan Pennell, MD, PhD of Cleveland Clinic discusses what’s next for his study on maintenance pembrolizumab for patients with small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8504: Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
Nathan Pennell, MD, PhD of Cleveland Clinic gives an overview of his abstract, which focused on the use of maintenance pembrolizumab in patients with extensive stage small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8504: Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
Nathan Pennell, MD, PhD of Cleveland Clinic discusses common questions that colleagues ask him regarding pembrolizumab, which is if there is a biomarker that can let clinicians know which patients will respond to the drug. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Nathan Pennell, MD, PhD of Cleveland Clinic summarizes promising presentations on targeted treatments in patients with non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis’ Lm Technology, which alters Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T-cells directed against cancer antigens. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains what axalimogene filolisbac is and the use of it in cervical cancer, specifically in the AIM2CERV trial. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the pipeline of Lm Technology at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains how Lm Technology works in the system and what are the advantages of the technology at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. summarizes the practice-changing studies on immuno-oncology coming out of ASCO 2017. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and Advaxis that is designed to activate a patient’s immune system to respond to certain mutations in the tumors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Andrew Norden, MD of IBM Watson Health discusses the future of Watson for Oncology in clinical practice at the 2017 ASCO Annual Meeting in Chicago, IL.
Andrew Norden, MD of IBM Watson Health summarizes the use of Watson technology in the field of oncology at the 2017 ASCO Annual Meeting in Chicago, IL.
Andrew Norden, MD of IBM Watson Health discusses questions and concerns colleagues have regarding Watson for Oncology, which include whether or not physicians will be replaced in the future due to this type of technology. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute discusses the next steps for his study, which include combining c-met targeted therapies with immunotherapy. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of his presentation, Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression, at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute summarizes the common questions colleagues ask him concerning his study on c-Met expression in renal cell carcinoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 4573: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression
Aly-Khan Lalani, MD of Dana-Farber Cancer Institute gives an overview of practice-changing data coming out of ASCO on metastatic hormone-sensitive prostate cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute gives an overview of his abstract, Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC), at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses common questions colleagues ask him regarding his abstract at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute discusses the impact of his study on clinical practice and future clinical research. He talks of his hopes for the increase in testing for the mutation and in utilization of MET inhibitors to patients. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Mark M. Awad, MD, PhD of Dana-Farber Cancer Institute summarizes the next steps for METdel14 mutations and MET inhibitors for non-small cell lung cancer at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8511: Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)